Research Topics
Species | C SeynaeveSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...- Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomyMurly Bm Tan
Department of Psychosocial Care, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Hered Cancer Clin Pract 7:6. 2009..This may help them arrive at an informed decision, to detect and manage psychological distress, and to plan psychological support services... - Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer casesPetra E A Huijts
Department of Clinical Genetics, K5 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
Breast Cancer Res 9:R78. 2007..Seven SNPs in five genomic loci were recently found to confer a mildly increased risk of breast cancer... - A family history of breast cancer will not predict female early onset breast cancer in a population-based settingGeertruida H de Bock
Department of Epidemiology, Groningen University Medical Center, Groningen, The Netherlands
BMC Cancer 8:203. 2008..The aim of the current study was to determine the predictive value of a family history of cancer with regard to early onset of female breast cancer in a population based setting... - Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer ClinicBernadette A M Heemskerk Gerritsen
Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Ann Surg Oncol 14:3335-44. 2007..Prophylactic mastectomy (PM) results in the greatest BC risk reduction. Long-term data on the efficacy and sequels of PM are scarce... 
Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapyC Seynaeve
Family Cancer Clinic, Department of Medical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Groene Hilledijk, 301, 3075 EA Rotterdam, The Netherlands
Eur J Cancer 40:1150-8. 2004..These data suggest an indication for long-term follow up in HBC and should be taken into account when additional 'risk-reducing' surgery after primary BCT is eventually considered...- Tailoring breast cancer therapy to genetic statusCaroline Seynaeve
Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Centre, 3075 AE Rotterdam, Netherlands
Lancet 365:1672-3. 2005 - Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective studyI van Oostrom
Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Clin Genet 71:35-42. 2007..Identifying individuals with insufficient sources of support and addressing the family communication concerning hereditary cancer in genetic counseling may help the counselee to adjust better to genetic testing... - Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer familiesL C Verhoog
Division of Tumour Endocrinology, Department of Medical Oncology, Daniel den Hoed Cancer Center, University Hospital, Rotterdam, The Netherlands
Eur J Cancer 37:2082-90. 2001..Thus, large regional differences exist in the prevalence of certain specific BRCA1/BRCA2 founder mutations, even in very small areas concerning populations of approximately 200000 inhabitants... - Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer casesC T M Brekelmans
Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, The Netherlands
Eur J Cancer 43:867-76. 2007..The prognostic impact of the classical tumour and treatment factors in hereditary BC is insufficiently known... - Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutationH Meijers-Heijboer
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
N Engl J Med 345:159-64. 2001..2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up... - Passive coping and psychological distress in women adhering to regular breast cancer surveillanceK Pieterse
Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Psychooncology 16:851-8. 2007..Coping style was not associated with the trend of psychological distress around the two surveillance appointments. It is recommendable to take coping styles into account when counselling these high-risk women... - Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancerL C Verhoog
Family Cancer Clinic, Department of Medical Oncology, Daniel den Hoed Cancer Centre, University Hospital Rotterdam, The Netherlands
Br J Cancer 83:384-6. 2000..02). These data suggest that age at diagnosis of the first tumour should be taken into account when prophylactic mastectomy in BRCA1-patients is considered... - Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trialA J ten Tije
Department of Medical Oncology, Erasmus MC Rotterdam Cancer Institute m Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
Eur J Cancer 40:352-7. 2004..Weekly paclitaxel at this dose and schedule is an effective treatment regimen in the elderly patient with metastatic breast cancer, and is feasible, but yields relevant fatigue in a subset of patients... - Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancerM M A Tilanus-Linthorst
Department of Surgical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
Br J Surg 93:961-8. 2006..This study investigated the influence of contralateral cancer and tumour stage on survival in patients with familial non-BRCA1/BRCA2-associated breast cancer... 
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
Clin Pharmacol Ther 92:62-7. 2012..Given the extensive metabolism undergone by tamoxifen, several factors may have contributed to this effect. Similar drug-drug interactions may exist between tamoxifen and other strong CYP inducers...- Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxaneC H Smorenburg
Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
Breast Cancer Res Treat 66:83-7. 2001..Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer... - Survival and prognostic factors in BRCA1-associated breast cancerC T M Brekelmans
Department of Medical Oncology, Department of Surgical Oncology and Department of Clinical Genetics, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Ann Oncol 17:391-400. 2006..Further, the prognostic impact of the classical tumour and treatment factors is unclear in BRCA1-associated BC... - The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerL A Lammers
Department of Hospital Pharmacy, Erasmus MC, University Hospital, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
Br J Cancer 103:765-71. 2010.... - Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patientsP M L H Vencken
Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Ann Oncol 22:1346-52. 2011.... - Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patientsC H Smorenburg
Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
Anticancer Drugs 11:825-8. 2000..9 months. In this study topically applied miltefosine for metastatic skin lesions of breast cancer showed modest activity in a relatively heavily pretreated patient population, without serious systemic toxicity... - Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testingI van Oostrom
Department of Clinical Genetics, Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Ann Oncol 17:1090-5. 2006..This study explores the effect of age at the time of parental cancer diagnosis or death on psychological distress and cancer risk perception in individuals undergoing genetic testing for a specific cancer susceptibility... - Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancerM Kriege
Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
Breast Cancer Res Treat 102:357-63. 2007.... - Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacyP Hamberg
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, Rotterdam, The Netherlands
Eur J Cancer 43:1514-28. 2007..As in other research areas, maximal progress will be achieved by joined efforts of co-operative research groups... - Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial riskC T Brekelmans
Department of Medical Oncology, Family Cancer Clinic, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Clin Oncol 19:924-30. 2001..The effectiveness of surveillance in high-risk women and especially BRCA1/2 mutation carriers is unknown. We present first results from a single large family cancer clinic... - Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ G Klijn
Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital Rotterdam, The Netherlands
J Natl Cancer Inst 92:903-11. 2000.... - Impact of screening for breast cancer in high-risk women on health-related quality of lifeA J Rijnsburger
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Br J Cancer 91:69-76. 2004..In this study, high-risk women who opted for regular breast cancer screening had a better health status than women from the general population... - The Distress Thermometer assessed in women at risk of developing hereditary breast cancerS Van Dooren
Department of Medical Psychology and Psychotherapy, Erasmus MC, 3000 CA Rotterdam, The Netherlands
Psychooncology 18:1080-7. 2009..Further, the women filled in an evaluation form... - The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomyP J C Bresser
Department of Medical Psychology and Psychotherapy, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Eur J Cancer 43:95-103. 2007..More research is needed to further define the characteristics of the women who continue to have clinically relevant increased scores after surgery, in order to offer them additional counselling... - Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapyA Snijders-Keilholz
Erasmus University Medical Center, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands
Gynecol Oncol 98:516-9. 2005..The treatment policies in these eight cases differed considerably, partly due to the rarity of the disease and to differing time periods of diagnosis and treatment... - [Preventive surgical prcedures for inherited risk of breast cancer]M B E Menke-Pluymers
Erasmus MC Daniel den Hoed Oncologisch Centrum, Postbus 5201, 3008 AE Rotterdam
Ned Tijdschr Geneeskd 149:2663-7. 2005..The complexity of the problem demands a multidisciplinary approach within the context of a family cancer clinic... - Women's acceptance of MRI in breast cancer surveillance because of a familial or genetic predispositionM L Essink-Bot
Department of Public Health, Erasmus MC University Medical Center Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Breast 15:673-6. 2006..MRI provided the most reassurance of breast cancer being absent in case of a favourable test result. MRI seems to be acceptable as a screening test for women at increased breast cancer risk and is preferred by them over mammography... - A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistanceJ Verweij
Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
Br J Cancer 64:361-4. 1991..Epidoxorubicin toxicities were as expected but the frequency of severe leucocytopenia was striking. This treatment schedule can not be considered active in colorectal cancer... - Novel endocrine therapies in breast cancerJ G Klijn
Department of Medical Oncology, Rotterdam Cancer Institute, Dr Daniel den Hoed Kliniek, The Netherlands
Acta Oncol 35:30-7. 1996..Future studies on treatment of all stages of disease will increasingly focus on promising combined treatment modalities... - Microsatellite instability in a pleomorphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancerM A den Bakker
Departments of Pathology and Medical Oncology, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
Histopathology 43:297-9. 2003..To describe the rare occurrence of a pleomorphic sarcoma with microsatellite instability in a patient with hereditary non-polyposis colorectal cancer (HNPCC)... - Psychological distress and breast self-examination frequency in women at increased risk for hereditary or familial breast cancerS Van Dooren
Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Community Genet 6:235-41. 2003..Surveillance consists of biannual physical examination, annual mammography, annual MRI and monthly breast self-examination (BSE)... - Clinical experience with venlafaxine in the treatment of hot flushes in women with a history of breast cancerA R Van Gool
Department of Psychiatry, Erasmus Medical Centre Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Neth J Med 63:175-8. 2005..To obtain practical experience with venlafaxine for hot flushes in breast cancer patients and incorporate this in a treatment protocol... - Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine originA W Oosten
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Sarcoma 2009:348910. 2009..If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender... - Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancerC H Smorenburg
Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Eur J Cancer 39:196-202. 2003..The clinical relevance of these observations with respect to toxicity profiles and antitumour efficacy requires further evaluation... - The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomasMetin Tascilar
Department of Medical Oncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands
Oncologist 12:1351-60. 2007..Furthermore, this review focuses on the anticipated growing role of ifosfamide in the development of new treatment strategies... - Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patientsMieke Kriege
Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
Breast Cancer Res Treat 111:303-11. 2008..Data on distant disease-free interval (DDFI) and the localization of the first distant metastasis (DM) in BRCA1- and BRCA2-associated breast cancer (BC) patients are as yet scarcely available... - The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective studyIris van Oostrom
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, The Netherlands
Psychooncology 16:1121-9. 2007..Identifying unhelpful representations and cognitive restructuring may be appropriate interventions to help distressed individuals undergoing genetic susceptibility testing for a BRCA1/2 or a HNPCC-related mutation... - Gynaecological sarcomasStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Curr Opin Oncol 19:492-6. 2007..To review gynaecological sarcomas, their management and future perspectives... - Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatmentStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Oncologist 12:719-26. 2007.... - GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial designJaap Verweij
Erasmus University Medical Center, Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
Adv Exp Med Biol 610:144-54. 2008 - Practical aspects of managing gastrointestinal stromal tumorsStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Clin Colorectal Cancer 6:S18-23. 2006..This review addresses several aspects of the current management of GIST as well as some novel developments... - Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testingIris van Oostrom
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Westzeedijk 112 114, 3016 AH, Rotterdam, The Netherlands
Eur J Cancer 43:71-7. 2007..Individuals who may benefit from additional support may be identified before result disclosure using a short instrument assessing the relevant aspects... - Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutationHanne Meijers-Heijboer
Rotterdam Family Cancer Center, Department of Clinical Genetics, The Netherlands
J Clin Oncol 21:1675-81. 2003..CONCLUSION: In a clinical setting, we show a high demand for BRCA1/BRCA2 testing and for prophylactic surgery by women with breast and/or ovarian cancer from high-risk families... - Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testingLitanja Lodder
Department of Medical Psychology and Psychotherapy, Erasmus University, Rotterdam Netherlands Institute for Health Sciences, The Netherlands
Am J Med Genet A 119:266-72. 2003..However, generalization of these results to women who neither underwent the test nor participated in a surveillance program should be considered with caution... - Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up studyIris van Oostrom
Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
J Clin Oncol 21:3867-74. 2003..To explore long-term psychosocial consequences of carrying a BRCA1/2 mutation and to identify possible risk factors for long-term psychological distress... - A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology aloneVibeke Kuenen-Boumeester
Department of Pathology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Hum Pathol 35:629-32. 2004..Surprisingly, at that time an occult breast carcinoma was identified to be the origin of the 2 metastatic locations as confirmed by molecular analysis. Eventually the patient could be treated accordingly... - Psychological distress in women at increased risk for breast cancer: the role of risk perceptionSilvia van Dooren
Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Eur J Cancer 40:2056-63. 2004..This knowledge should be used during surveillance appointments in order to improve and individualise support for these women... - The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancerSilvia van Dooren
Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Breast Cancer Res Treat 89:75-80. 2005..Being at hereditary risk of breast cancer (BC) may lead to elevated levels of distress because of the impact of the BC-process in relatives... - Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancerPaul A M Meeuwissen
Family Cancer Clinic, The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Erasmus University Medical Centre Rotterdam, Room H585, Dr Molewaterplein 40, 3000 CC Rotterdam, The Netherlands
Gynecol Oncol 97:476-82. 2005..It is important to inform high-risk women of these limitations. For now, prophylactic bilateral salpingo-oophorectomy remains the optimal risk-reducing strategy for women at high risk... - Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastasesSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 20:1543-7. 2005..The apparent relationships between skeletal retention and antiresorptive effect could have implications for the design of optimal therapeutic regimens with BPs in patients with bone metastases from breast cancer... - Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group ofMarijke Bontenbal
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Clin Oncol 23:7081-8. 2005..To compare the efficacy and safety of doxorubicin and docetaxel (AT) with fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line chemotherapy for metastatic breast cancer (MBC)... - Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal studyPeter Nieboer
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
J Clin Oncol 23:8296-304. 2005..CONCLUSION: In 3 years after treatment, no significant differences in fatigue were found between standard and high-dose chemotherapy. Fatigue did not change over time. The strongest fatigue predictor was poor mental health... - A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationshipsIris van Oostrom
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Westzeedijk 114, 3016 AH Rotterdam, The Netherlands
Psychooncology 16:320-8. 2007..Open communication between relatives should be stimulated because a lack of open communication may be an important determinant of familial adverse effects... - Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distressIris van Oostrom
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, The
Patient Educ Couns 65:58-68. 2007..To study differences between individuals opting for genetic cancer susceptibility testing of a known familial BRCA1/2 and HNPCC related germline mutation... - Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancerMieke Kriege
Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Breast Cancer Res Treat 100:109-19. 2006..227) and for women with a low breast density (0.237). CONCLUSIONS: This report supports the earlier recommendation that MRI should be a standard screening method for breast cancer in BRCA1/2 mutation carriers... - Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed womenPaula J C Bresser
Department of Medical Psychology, The Daniel den Hoed Cancer Center, Erasmus Medical Center, Rotterdam, The Netherlands
Plast Reconstr Surg 117:1675-82; discussion 1683-4. 2006..In the present follow-up study, the authors assess satisfaction with prophylactic mastectomy and breast reconstruction and its impact on sexual relationships... - Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?Cecile T M Brekelmans
Lancet Oncol 7:191-3. 2006 - Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancerSilvia van Dooren
Department of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Eur J Cancer 41:1416-25. 2005..The course of general distress differed significantly for women closely involved in a sister's BC-process. These more vulnerable subgroups may be in need of extra counselling and care... - Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard careStefan Sleijfer
Department of Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre, Rotterdam, The Netherlands
Oncologist 10:833-41. 2005..This review also focuses on these and other strategies that will hopefully lead to better out comes in this disease entity in the near future... - One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery)Litanja N Lodder
Department of Medical Psychology, Erasmus University Rotterdam, Netherlands Institute for Health Sciences
Breast Cancer Res Treat 73:97-112. 2002..This might explain, why most women who underwent prophylactic mastectomy were satisfied with this decision, despite a perceived negative impact on body image, the intimate relationship and physical wellbeing... - Targeted therapy: ready for prime time?Caroline Seynaeve
Dept of Medical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Cancer Treat Res 120:1-15. 2004